UCI THERAPEUTICS
UCI THERAPEUTICS
Industry:
Biotechnology Therapeutics
Address:
Pohang, Kyongsang-bukto, South Korea
Country:
South Korea
Website Url:
http://www.uci-therapeutics.co.kr
Status:
Active
Contact:
+82 026 466 3636
Email Addresses:
[email protected]
Total Funding:
4.35 B KRW
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Amrita Therapeutics
Amrita Therapeutics is a biopharmaceutical company.
Artesian Therapeutics
Artesian Therapeutics is a biopharmaceutical company.
Barrett Hodgson
Barrett Hodgson is a pharmaceutical company.
Hager Biosciences
Hager Biosciences is a biopharmaceutical company.
Mucokinetica
Mucokinetica is a biopharmaceutical company
Northern Therapeutics
Northern Therapeutics is a biopharmaceutical company
Oncoscience
Oncoscience is a biopharmaceutical company
Sparian Biosciences
Sparian Biosciences is a biopharmaceutical company.
Investors List
Pathfinder H
Pathfinder H investment in Seed Round - UCI Therapeutics
Smilegate Investment
Smilegate Investment investment in Seed Round - UCI Therapeutics
POSCO CAPITAL
POSCO CAPITAL investment in Seed Round - UCI Therapeutics
Gyeongnam Venture Investment
Gyeongnam Venture Investment investment in Seed Round - UCI Therapeutics
Dt& Investment
Dt& Investment investment in Seed Round - UCI Therapeutics
Seoul Business Agency(SBA)
Seoul Business Agency(SBA) investment in Seed Round - UCI Therapeutics
MMS Ventures
MMS Ventures investment in Seed Round - UCI Therapeutics
Official Site Inspections
http://www.uci-therapeutics.co.kr
- Host name: 183.111.161.223
- IP address: 183.111.161.223
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "UCI Therapeutics"
UCI Therapeutics
Tel. 02-6466-3636 | Fax. 02-6455-5576 | Email. [email protected] 사업자등록번호 : 691-88-01822 | 대표 : 정수영 지점 : 서울특별시 성동구 성수이로 10길 14, 605호See details»
UCI Therapeutics - Crunchbase Company Profile
UCI Therapeutics closed its last funding round on May 25, 2022 from a Seed round. Who are UCI Therapeutics 's competitors? Alternatives and possible …See details»
UCI therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for UCI therapeutics Inc. of Pohang, Gyeongbuk. Get the latest business insights from Dun & Bradstreet.See details»
UCI Therapeutics - Company Profile - Tracxn
Oct 12, 2024 UCI Therapeutics company profile. Developer od targeted cell therapies for the treatment of cancer. 2020 • Pohang si (South Korea) • Funding Raised • Pohang si (South …See details»
UCI Therapeutics - PitchBook
UCI Therapeutics General Information Description. Operator of a biopharmaceutical company intended to overcome the shortcomings of …See details»
UCI Therapeutics Inc. - Drug pipelines, Patents, Clinical trials
Explore UCI Therapeutics Inc. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, Hemic and Lymphatic …See details»
UCI Therapeutics - Products, Competitors, Financials, Employees ...
Uci-therapeutics.co.kr. Overview & Products; Financials; Founded Year 2020. Stage Seed VC | Alive. Total Raised $3.41M. Last Raised $3.31M | 3 yrs ago. About UCI Therapeutics. UCI …See details»
UCI Therapeutics
UCI Therapeutics is a dynamic startup pioneering innovation in the field of biopharmaceuticals, with a motto of 'Designing Innovative Biological Medicines.' Our mission is to leverage the …See details»
GC Cell signs contract with UCI Therapeutics for CAR …
Jul 10, 2024 Founded in 2020, UCI Therapeutics is a bio-venture company that develops CAR-NK immunotherapy based on NK cell engineering technology. CAR-NK is a cell therapy that combines chimeric antigen receptor (CAR), …See details»
UCI Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . May 25, 2022: ... Seed Round - …See details»
유씨아이테라퓨틱스, CAR-NK 세포 고형암 효과…국제학술지 게재
Oct 28, 2024 [프레스나인] CAR-NK 세포유전자치료제 개발 업체인 UCI Therapeutics(이하 유씨아이테라퓨틱스)는 한국과학기술연구원(KIST) 장미희 박사 연구팀과 공동 연구를 통해, …See details»
UCI-113 - Drug Targets, Indications, Patents - Synapse - Patsnap
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Synergistic therapeutic combination with a CAF inhibitor ... - PubMed
4 Corporate Research & Development Center, UCI therapeutics, Seoul, Korea (the Republic of). ... Seoul, Korea (the Republic of) [email protected] [email protected] …See details»
UCI-100 - Drug Targets, Indications, Patents - Synapse - Patsnap
UCI-100, Initially developed by UCI Therapeutics Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Solid tumor, Active Org.: UCI …See details»
Empowering pancreatic tumor homing with augmented anti …
E-mail: [email protected] Correspondence: Mihue Jang, Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, …See details»
UCI-114 - Drug Targets, Indications, Patents - Synapse
Last update 30 Nov 2024. UCI-114. Last update 30 Nov 2024See details»
UCI-11X - Drug Targets, Indications, Patents - Synapse
UCI-11X, Initially developed by UCI Therapeutics Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org.: UCI …See details»
UCI121 - Drug Targets, Indications, Patents - Synapse
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
UCI-1101 - Drug Targets, Indications, Patents - Synapse - Patsnap
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
UCI-101 - Drug Targets, Indications, Patents - Synapse
UCI-101: a CD19 inhibitors, CD22 inhibitors Drug, Initially developed by UCI Therapeutics Inc., Now, its global highest R&D status is Preclinical, Mechanism: CD19 inhibitors(B-lymphocyte …See details»